Free Trial
→ Musk’s Project Colossus could mint millionaires (From Brownstone Research) (Ad) Buy TLX Stock  Free TLX Stock Alerts

Telix Pharmaceuticals Limited American Depositary Shares (TLX) Financials

Telix Pharmaceuticals Limited American Depositary Shares logo
$16.60 +0.40 (+2.47%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$16.64 +0.04 (+0.27%)
As of 05/23/2025 05:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Telix Pharmaceuticals Limited American Depositary Shares

Annual Income Statements for Telix Pharmaceuticals Limited American Depositary Shares

This table shows Telix Pharmaceuticals Limited American Depositary Shares' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Income / (Loss) Attributable to Common Shareholders		 31 2.83 -71
Consolidated Net Income / (Loss)		 31 3.56 -71
Net Income / (Loss) Continuing Operations		 47 2.83 -68
Total Pre-Tax Income 		35 2.11 -67
Total Operating Income		 51 1.99 -63
Total Gross Profit		 315 215 65
Total Revenue		 484 319 109
Operating Revenue		 484 344 109
Total Cost of Revenue		 169 141 44
Operating Cost of Revenue		 169 141 44
Total Operating Expenses		 254 176 112
Selling, General & Admin Expense		 80 51 32
Marketing Expense		 53 34 25
Research & Development Expense		 120 88 55
Total Other Income / (Expense), net		 -11 -0.61 -17
Interest Expense		 23 - 4.55
Interest & Investment Income		 6.72 -0.61 0.00
Other Income / (Expense), net		 5.02 - -13
Income Tax Expense		 3.80 -1.45 3.71
Basic Earnings per Share		 $9.32 - ($22.80)
Weighted Average Basic Shares Outstanding		 334.72M - -
Diluted Earnings per Share		 $8.94 - ($22.80)
Weighted Average Diluted Shares Outstanding		 334.72M - -
Weighted Average Basic & Diluted Shares Outstanding		 334.72M - -

Quarterly Income Statements for Telix Pharmaceuticals Limited American Depositary Shares

No quarterly income statements for Telix Pharmaceuticals Limited American Depositary Shares are available.

Annual Cash Flow Statements for Telix Pharmaceuticals Limited American Depositary Shares

This table details how cash moves in and out of Telix Pharmaceuticals Limited American Depositary Shares' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Change in Cash & Equivalents		 338 38 81
Net Cash From Operating Activities		 27 -279 -16
Net Cash From Continuing Operating Activities		 2.05 -279 -16
Net Income / (Loss) Continuing Operations		 0.00 0.00 0.00
Changes in Operating Assets and Liabilities, net		 2.05 - -
Net Cash From Investing Activities		 -84 317 84
Net Cash From Continuing Investing Activities		 -81 317 84
Purchase of Property, Plant & Equipment		 -21 - -
Acquisitions		 -19 - -
Purchase of Investments		 -41 - -
Net Cash From Financing Activities		 395 0.00 13
Net Cash From Continuing Financing Activities		 395 0.00 13
Repayment of Debt		 -1.94 - -
Issuance of Debt		 396 - -
Other Financing Activities, net		 0.62 0.00 13

Quarterly Cash Flow Statements for Telix Pharmaceuticals Limited American Depositary Shares

No quarterly cash flow statements for Telix Pharmaceuticals Limited American Depositary Shares are available.

Annual Balance Sheets for Telix Pharmaceuticals Limited American Depositary Shares

This table presents Telix Pharmaceuticals Limited American Depositary Shares' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023
Period end date 12/31/2024 12/31/2023
Total Assets		 938 277
Total Current Assets		 568 159
Cash & Equivalents		 439 84
Accounts Receivable		 86 44
Inventories, net		 24 12
Current Deferred & Refundable Income Taxes		 5.88 5.23
Other Current Assets		 13 13
Plant, Property, & Equipment, net		 28 16
Plant, Property & Equipment, gross		 28 16
Total Noncurrent Assets		 342 103
Long-Term Investments		 35 8.37
Intangible Assets		 257 75
Noncurrent Deferred & Refundable Income Taxes		 29 14
Other Noncurrent Operating Assets		 21 5.40
Total Liabilities & Shareholders' Equity		 836 247
Total Liabilities		 586 176
Total Current Liabilities		 205 113
Short-Term Debt		 12 0.66
Accounts Payable		 87 56
Current Deferred & Payable Income Tax Liabilities		 30 13
Other Current Liabilities		 9.08 8.31
Total Noncurrent Liabilities		 382 63
Long-Term Debt		 341 5.61
Capital Lease Obligations		 5.04 5.24
Noncurrent Deferred & Payable Income Tax Liabilities		 5.80 0.00
Other Noncurrent Operating Liabilities		 11 14
Total Equity & Noncontrolling Interests		 351 102
Total Preferred & Common Equity		 336 145
Total Common Equity		 336 145
Common Stock		 369 305
Retained Earnings		 -132 -180
Other Equity Adjustments		 98 20

Quarterly Balance Sheets for Telix Pharmaceuticals Limited American Depositary Shares

No quarterly balance sheets for Telix Pharmaceuticals Limited American Depositary Shares are available.

Annual Metrics And Ratios for Telix Pharmaceuticals Limited American Depositary Shares

This table displays calculated financial ratios and metrics derived from Telix Pharmaceuticals Limited American Depositary Shares' official financial filings.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Growth Metrics		 - - -
Revenue Growth		 51.69% 193.13% 0.00%
EBITDA Growth		 2,709.41% 102.64% 0.00%
EBIT Growth		 2,709.41% 102.64% 0.00%
NOPAT Growth		 1,248.70% 107.66% 0.00%
Net Income Growth		 767.74% 105.02% 0.00%
EPS Growth		 0.00% 0.00% 0.00%
Operating Cash Flow Growth		 109.55% -1,631.30% 0.00%
Free Cash Flow Firm Growth		 -102.39% 0.00% 0.00%
Invested Capital Growth		 243.41% 0.00% 0.00%
Revenue Q/Q Growth		 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00%
Profitability Metrics		 - - -
Gross Margin		 65.08% 67.22% 59.29%
EBITDA Margin		 11.52% 0.62% -69.13%
Operating Margin		 10.49% 0.62% -57.42%
EBIT Margin		 11.52% 0.62% -69.13%
Profit (Net Income) Margin		 6.37% 1.11% -65.01%
Tax Burden Percent		 89.05% 168.80% 105.53%
Interest Burden Percent		 62.11% 106.08% 89.10%
Effective Tax Rate		 10.95% -68.80% 0.00%
Return on Invested Capital (ROIC)		 21.77% 7.16% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 98.27% 2.03% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 -8.14% -0.16% 0.00%
Return on Equity (ROE)		 13.63% 7.00% 0.00%
Cash Return on Invested Capital (CROIC)		 -88.02% -192.84% 0.00%
Operating Return on Assets (OROA)		 9.19% 0.72% 0.00%
Return on Assets (ROA)		 5.08% 1.28% 0.00%
Return on Common Equity (ROCE)		 14.44% 9.95% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 9.20% 2.46% 0.00%
Net Operating Profit after Tax (NOPAT)		 45 3.35 -44
NOPAT Margin		 9.34% 1.05% -40.20%
Net Nonoperating Expense Percent (NNEP)		 -76.50% 5.13% 0.00%
Return On Investment Capital (ROIC_SIMPLE)		 6.38% 2.96% -
Cost of Revenue to Revenue		 34.92% 44.28% 40.71%
SG&A Expenses to Revenue		 16.58% 15.86% 29.45%
R&D to Revenue		 24.85% 27.48% 50.40%
Operating Expenses to Revenue		 52.34% 55.09% 102.54%
Earnings before Interest and Taxes (EBIT)		 56 1.99 -75
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 56 1.99 -75
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 15.36 1.40 0.00
Price to Tangible Book Value (P/TBV)		 65.97 2.90 0.00
Price to Revenue (P/Rev)		 10.64 0.63 1.85
Price to Earnings (P/E)		 166.96 71.40 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.60% 1.40% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 15.66 1.29 0.00
Enterprise Value to Revenue (EV/Rev)		 10.40 0.38 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 90.27 60.79 0.00
Enterprise Value to EBIT (EV/EBIT)		 90.27 60.79 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 111.39 36.01 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 189.33 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 1.02 0.11 0.00
Long-Term Debt to Equity		 0.99 0.11 0.00
Financial Leverage		 -0.08 -0.08 0.00
Leverage Ratio		 2.68 2.73 0.00
Compound Leverage Factor		 1.67 2.89 0.00
Debt to Total Capital		 50.47% 10.17% 0.00%
Short-Term Debt to Total Capital		 1.66% 0.58% 0.00%
Long-Term Debt to Total Capital		 48.81% 9.58% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00%
Common Equity to Total Capital		 47.29% 127.74% 0.00%
Debt to EBITDA		 6.41 5.79 0.00
Net Debt to EBITDA		 -2.08 -40.77 0.00
Long-Term Debt to EBITDA		 6.20 5.46 0.00
Debt to NOPAT		 7.92 3.43 0.00
Net Debt to NOPAT		 -2.56 -24.15 0.00
Long-Term Debt to NOPAT		 7.66 3.23 0.00
Altman Z-Score		 6.26 1.16 0.00
Noncontrolling Interest Sharing Ratio		 -5.95% -42.19% 0.00%
Liquidity Ratios		 - - -
Current Ratio		 2.78 1.41 0.00
Quick Ratio		 2.57 1.14 0.00
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 -183 -90 0.00
Operating Cash Flow to CapEx		 126.44% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -8.01 0.00 0.00
Operating Cash Flow to Interest Expense		 1.17 0.00 -3.53
Operating Cash Flow Less CapEx to Interest Expense		 0.24 0.00 -3.53
Efficiency Ratios		 - - -
Asset Turnover		 0.80 1.15 0.00
Accounts Receivable Turnover		 7.43 7.22 0.00
Inventory Turnover		 9.56 11.97 0.00
Fixed Asset Turnover		 22.21 20.19 0.00
Accounts Payable Turnover		 2.38 2.54 0.00
Days Sales Outstanding (DSO)		 49.16 50.55 0.00
Days Inventory Outstanding (DIO)		 38.20 30.50 0.00
Days Payable Outstanding (DPO)		 153.54 143.98 0.00
Cash Conversion Cycle (CCC)		 -66.18 -62.93 0.00
Capital & Investment Metrics		 - - -
Invested Capital		 322 94 0.00
Invested Capital Turnover		 2.33 6.82 0.00
Increase / (Decrease) in Invested Capital		 228 94 0.00
Enterprise Value (EV)		 5,039 121 0.00
Market Capitalization		 5,155 202 202
Book Value per Share		 $1.00 $8.50 $0.00
Tangible Book Value per Share		 $0.23 $4.10 $0.00
Total Capital		 710 113 0.00
Total Debt		 358 12 0.00
Total Long-Term Debt		 346 11 0.00
Net Debt		 -116 -81 0.00
Capital Expenditures (CapEx)		 21 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -64 -37 0.00
Debt-free Net Working Capital (DFNWC)		 375 47 0.00
Net Working Capital (NWC)		 363 46 0.00
Net Nonoperating Expense (NNE)		 14 -0.20 27
Net Nonoperating Obligations (NNO)		 -30 -7.96 0.00
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 -13.24% -11.72% 0.00%
Debt-free Net Working Capital to Revenue		 77.46% 14.63% 0.00%
Net Working Capital to Revenue		 75.03% 14.42% 0.00%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 $9.32 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 334.72M 0.00 0.00
Adjusted Diluted Earnings per Share		 $8.94 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 334.72M 0.00 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 334.72M 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 45 1.39 -44
Normalized NOPAT Margin		 9.34% 0.44% -40.20%
Pre Tax Income Margin		 7.16% 0.66% -61.60%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 2.44 0.00 -16.54
NOPAT to Interest Expense		 1.98 0.00 -9.61
EBIT Less CapEx to Interest Expense		 1.52 0.00 -16.54
NOPAT Less CapEx to Interest Expense		 1.06 0.00 -9.61
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Telix Pharmaceuticals Limited American Depositary Shares

No quarterly metrics and ratios for Telix Pharmaceuticals Limited American Depositary Shares are available.

Frequently Asked Questions About Telix Pharmaceuticals Limited American Depositary Shares' Financials

When does Telix Pharmaceuticals Limited American Depositary Shares's fiscal year end?

According to the most recent income statement we have on file, Telix Pharmaceuticals Limited American Depositary Shares' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Telix Pharmaceuticals Limited American Depositary Shares' net income changed over the last 2 years?

Telix Pharmaceuticals Limited American Depositary Shares' net income appears to be on a downward trend, with a most recent value of $30.87 million in 2024, falling from -$70.83 million in 2022. The previous period was $3.56 million in 2023. View Telix Pharmaceuticals Limited American Depositary Shares' forecast to see where analysts expect Telix Pharmaceuticals Limited American Depositary Shares to go next.

What is Telix Pharmaceuticals Limited American Depositary Shares's operating income?
Telix Pharmaceuticals Limited American Depositary Shares's total operating income in 2024 was $50.80 million, based on the following breakdown:
  • Total Gross Profit: $315.24 million
  • Total Operating Expenses: $253.55 million
How has Telix Pharmaceuticals Limited American Depositary Shares revenue changed over the last 2 years?

Over the last 2 years, Telix Pharmaceuticals Limited American Depositary Shares' total revenue changed from $108.95 million in 2022 to $484.41 million in 2024, a change of 344.6%.

How much debt does Telix Pharmaceuticals Limited American Depositary Shares have?

Telix Pharmaceuticals Limited American Depositary Shares' total liabilities were at $586.47 million at the end of 2024, a 234.2% increase from 2023, and a 234.2% increase since 2023.

How much cash does Telix Pharmaceuticals Limited American Depositary Shares have?

In the past 1 years, Telix Pharmaceuticals Limited American Depositary Shares' cash and equivalents has ranged from $84.15 million in 2023 to $439.35 million in 2024, and is currently $439.35 million as of their latest financial filing in 2024.

How has Telix Pharmaceuticals Limited American Depositary Shares' book value per share changed over the last 2 years?

Over the last 2 years, Telix Pharmaceuticals Limited American Depositary Shares' book value per share changed from 0.00 in 2022 to 1.00 in 2024, a change of 100.2%.


Related Companies

This page (NASDAQ:TLX) was last updated on 5/25/2025 by MarketBeat.com Staff
From Our Partners
Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...
Premier Gold Co | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored
Is President Trump Lying To You With This?
President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...
Colonial Metals | Sponsored
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...
Porter & Company | Sponsored
Trump’s Bitcoin Reserve is No Accident…
Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...
Crypto 101 Media | Sponsored
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...
Crypto Swap Profits | Sponsored
Massive new energy source found in Utah
NEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...
Stansberry Research | Sponsored